Drug intelligence / Profile preview

M012

Development stage: Unknown
Lead developer: Merganser Biotech
Modality: Peptides
Administration: Oral, Inhalation, Topical

Overview

M012 is a lead compound developed by Merganser Biotech, classified as a minihepcidin and hepcidin mimetic peptide. It is designed to treat rare hematological and iron overload diseases such as Beta Thalassemia, Polycythemia Vera, and Hemochromatosis by restricting iron absorption. The technology behind M012 originated from preclinical research at Children's Hospital of Philadelphia (CHOP) and Weill Cornell Medical College, and was licensed from UCLA. Merganser Biotech secured $28 million in Series A financing in February 2015 to advance M012 into clinical development, including Phase 1 trials.

Targets

SLC40A1 (Ferroportin)

Beyond the preview

Go deeper on M012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on M012.

Explore the full profile